These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29061782)

  • 1. Development and
    Urey C; Hilmersson KS; Andersson B; Ansari D; Andersson R
    Anticancer Res; 2017 Nov; 37(11):6031-6039. PubMed ID: 29061782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
    Avan A; Quint K; Nicolini F; Funel N; Frampton AE; Maftouh M; Pelliccioni S; Schuurhuis GJ; Peters GJ; Giovannetti E
    Curr Pharm Des; 2013; 19(5):940-50. PubMed ID: 22973962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
    Al-Ejeh F; Pajic M; Shi W; Kalimutho M; Miranda M; Nagrial AM; Chou A; Biankin AV; Grimmond SM; ; Brown MP; Khanna KK
    Clin Cancer Res; 2014 Jun; 20(12):3187-97. PubMed ID: 24838526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans.
    Sagar S; Leiphrakpam PD; Thomas D; McAndrews KL; Caffrey TC; Swanson BJ; Clausen H; Wandall HH; Hollingsworth MA; Radhakrishnan P
    Cancer Lett; 2021 Apr; 503():91-102. PubMed ID: 33485947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin.
    Bafna S; Kaur S; Momi N; Batra SK
    Br J Cancer; 2009 Oct; 101(7):1155-61. PubMed ID: 19738614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apicidin sensitizes pancreatic cancer cells to gemcitabine by epigenetically regulating MUC4 expression.
    Ansari D; Urey C; Hilmersson KS; Bauden MP; Ek F; Olsson R; Andersson R
    Anticancer Res; 2014 Oct; 34(10):5269-76. PubMed ID: 25275019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine.
    Urey C; Andersson B; Ansari D; Sasor A; Said-Hilmersson K; Nilsson J; Andersson R
    Scand J Gastroenterol; 2017 May; 52(5):595-600. PubMed ID: 28270046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and In Vitro Evaluation of Long Circulating Liposomes for Targeted Delivery of Gemcitabine and Irinotecan in Pancreatic Ductal Adenocarcinoma.
    Deodhar S; Dash AK; North EJ; Hulce M
    AAPS PharmSciTech; 2020 Aug; 21(6):231. PubMed ID: 32778980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
    Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
    Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
    Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
    Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine-Lipid Conjugate and ONC201 Combination Therapy Effectively Treats Orthotopic Pancreatic Tumor-Bearing Mice.
    Shrestha P; Ghanwatkar Y; Mahto S; Pramanik N; Mahato RI
    ACS Appl Mater Interfaces; 2024 Jun; 16(23):29686-29698. PubMed ID: 38813771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hybrid Nanoparticles of Extracellular Vesicles and Gemcitabine Prodrug-Loaded Liposomes with Enhanced Targeting Ability for Effective PDAC Treatment.
    Kim B; Park H; Liu H; Kim S; Lee YK; Kim YC
    ACS Appl Bio Mater; 2024 Sep; 7(9):6025-6033. PubMed ID: 39231306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells.
    Cascioferro S; Petri GL; Parrino B; Carbone D; Funel N; Bergonzini C; Mantini G; Dekker H; Geerke D; Peters GJ; Cirrincione G; Giovannetti E; Diana P
    Eur J Med Chem; 2020 Mar; 189():112088. PubMed ID: 32007666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies.
    Mimeault M; Johansson SL; Senapati S; Momi N; Chakraborty S; Batra SK
    Cancer Lett; 2010 Sep; 295(1):69-84. PubMed ID: 20303649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
    Wissniowski TT; Meister S; Hahn EG; Kalden JR; Voll R; Ocker M
    Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
    Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
    Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
    J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.